ADR Biomedical HoldingsTSE:3750 -1.23%30 PB Ratio is 326.31 as of Jul. 09, 2026, which is 11853% above its 10-year median of 2.73. GuruFocus rates TSE:3750 with a GF Score™ of 30/100 and a GF Value™ of 円40.42 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 1,226 Biotechnology companies, ADR Biomedical Holdings ranks worse than 99.92% on this metric.
ADR Biomedical Holdings Inc stock PB Ratio (=330.36) is close to 10-year high of 342.12.
The historical rank and industry rank for ADR Biomedical Holdings's PB Ratio or its related term are showing as below:
TSE:3750'
s PB Ratio Range Over the Past 10 Years
Min: 0.44 Med: 2.73 Max: 342.12
Current: 326.31
During the past 13 years, ADR Biomedical Holdings's highest PB Ratio was 342.12. The lowest was 0.44. And the median was 2.73.
TSE:3750's PB Ratio is ranked worse than 99.92% of 1226
companies
in the Biotechnology industry
Industry Median: 2.89
vs TSE:3750: 326.31
During the past 12 months, ADR Biomedical Holdings's average Book Value Per Share Growth Rate was -96.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -79.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -58.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -27.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of ADR Biomedical Holdings was 13.40% per year. The lowest was -79.80% per year. And the median was -6.65% per year.
Back to Basics: PB Ratio
ADR Biomedical Holdings (TSE:3750) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ADR Biomedical Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADR Biomedical Holdings PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADR Biomedical Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where ADR Biomedical Holdings's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
ADR Biomedical Holdings (TSE:3750) has a PB Ratio of 326.31 as of Jul. 09, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ADR Biomedical Holdings and its competitors. This is 11853% above median its historical median of 2.73. Over the past decade, ADR Biomedical Holdings' PB Ratio has ranged from 0.44 to 342.12. According to the industry distribution chart, ADR Biomedical Holdings ranks #1225 out of 1226 companies in the Biotechnology industry, placing it in the top 99.9%.
Is ADR Biomedical Holdings' PB Ratio too high?
ADR Biomedical Holdings' current PB Ratio of 326.31 is 11853% above median its 10-year median of 2.73. Over the past 10 years, this metric has ranged from a low of 0.44 to a high of 342.12. The Biotechnology industry median PB Ratio is 2.89. ADR Biomedical Holdings' value of 326.31 is 11191% above this industry median. Based on the distribution chart, ADR Biomedical Holdings ranks #1225 out of 1226 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ADR Biomedical Holdings has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ADR Biomedical Holdings' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ADR Biomedical Holdings ranks #1225 out of 1226 companies for PB Ratio. This places ADR Biomedical Holdings in the lower half of its industry. The industry median PB Ratio is 2.89. ADR Biomedical Holdings' value of 326.31 is 11191% above this benchmark. Historically, ADR Biomedical Holdings' own PB Ratio has ranged from 0.44 to 342.12 over the past decade. While the company's 10-year median is 2.73 vs. the industry median of 2.89, ADR Biomedical Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.89, based on 1,226 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADR Biomedical Holdings's current PB Ratio of 326.31 is 11191% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ADR Biomedical Holdings and its competitors. For the Biotechnology industry, the median PB Ratio is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADR Biomedical Holdings's current PB Ratio is 326.31, which is 11853% above median its own 10-year median of 2.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADR Biomedical Holdings stock overvalued right now?
Based on GuruFocus' analysis, ADR Biomedical Holdings (TSE:3750) is currently considered Significantly Overvalued. The stock's GF Value™ is 円40.42, compared to a current price of 円805.00 — trading 1891.6% above its estimated fair value. The current PB Ratio is 326.31, which is 11853% above median its 10-year median of 2.73 and 11191% above the Biotechnology industry median of 2.89. ADR Biomedical Holdings' overall GF Score™ is 30/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For ADR Biomedical Holdings (TSE:3750), the current PB Ratio is 326.31 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADR Biomedical Holdings (TSE:3750) Overvalued in 2026?
Based on GuruFocus' analysis, ADR Biomedical Holdings stock appears to be overvalued.
The current stock price of 円805.00 is trading 1891.6% above its estimated GF Value™ of 円40.42.
GuruFocus considers ADR Biomedical Holdings to be Significantly Overvalued.
Key valuation signals for TSE:3750:
PB Ratio: 326.31 (11853% above median its 10-year median of 2.73)
GF Value™: 円40.42 vs. price of 円805.00 (1891.6% above fair value)
Industry Position: 11191% above the Biotechnology median (#1225 of 1226)
No single metric tells the full story. See the TSE:3750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADR120S Inc developing a new clinical approach to cell therapy to provide medical care to patients by providing medical care that responds to unmet medical needs based on its regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.
30GF Score
Get the complete analysis for TSE:3750
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3750 has been successfully added to your 
